Nadia Dac

Corporate Officer/Principal presso OMEROS CORPORATION

54 anni

Health Technology

Consumer Services

Profilo

Nadia Dac currently works at Omeros Corp., as Chief Commercial Officer from 2021.
Ms. Dac also formerly worked at Auxilium Pharmaceuticals LLC, as Vice President-Marketing from 2013 to 2014, AbbVie, Inc., as VP-Global Specialty Commercial Development from 2014 to 2019, Novartis AG, as VP-Neuroscience Professional Relations from 2009 to 2013, and Lundbeck Seattle BioPharmaceuticals, Inc., as Chief Commercial Officer from 2019 to 2020.
Ms. Dac received her undergraduate degree from Rutgers State University of New Jersey.

Posizioni attive di Nadia Dac

Società	Posizione	Inizio
OMEROS CORPORATION	Corporate Officer/Principal	26/01/2021

Tutte le posizioni attive di Nadia Dac

Precedenti posizioni note di Nadia Dac

Società	Posizione	Fine
ALDER BIOPHARMACEUTICALS, INC.	Corporate Officer/Principal	01/06/2020
ABBVIE INC.	Corporate Officer/Principal	01/03/2019
AUXILIUM PHARMACEUTICALS, INC.	Vendite & Marketing	01/09/2014
NOVARTIS AG	Corporate Officer/Principal	01/01/2013

Vedi nel dettaglio l'esperienza di Nadia Dac

Formazione di Nadia Dac

Rutgers State University of New Jersey

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Nadia Dac

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	3
OMEROS CORPORATION	Health Technology
ABBVIE INC.	Health Technology
NOVARTIS AG	Health Technology

Aziende private	2
Lundbeck Seattle BioPharmaceuticals, Inc. Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.	Health Technology
Auxilium Pharmaceuticals LLC Auxilium Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Auxilium Pharmaceuticals LLC develops and markets pharmaceutical products. It specializes in men's healthcare area and has product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The firm products include edex, Osbon, ErecAid, STENDRA, TESTOPEL, XIAFLEX and Testim. The company was founded by Gerri A. Henwood and Jane Holmes Hollingsworth in 1999 and is headquartered in Chesterbrook, PA.	Health Technology